Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial-Reference-Cited by-同舟云学术

Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial

Published:2019-09 Issue: Volume:118 Page:178-186
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Perrone Francesco^ORCID,De Laurentiis Michelino,De Placido Sabino,Orditura Michele,Cinieri Saverio,Riccardi Ferdinando,Ribecco Angela Stefania,Putzu Carlo,Del Mastro Lucia,Rossi Emanuela,Tinessa Vincenza,Mosconi Anna Maria,Nuzzo Francesco,Di Rella Francesca,Gravina Adriano,Iodice Giovanni,Landi Gabriella,Pacilio Carmen,Forestieri Valeria,Lauria Rossella,Fabbri Agnese,Ibrahim Toni,De Maio Ermelinda,Barni Sandro,Gori Stefania^ORCID,Simeon Vittorio,Arenare Laura,Daniele Gennaro^ORCID,Piccirillo Maria Carmela,Normanno Nicola,de Matteis Andrea,Gallo Ciro

Funder

Associazione Italiana per la Ricerca sul Cancro (AIRC)

Novartis

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference22 articles.

1. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials;Early Breast Cancer Trialists' Collaborative;Lancet,2005

2. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009;Goldhirsch;Ann Oncol:Off J Eur Soc Med Oncol,2009

3. Tailoring adjuvant endocrine therapy for premenopausal breast cancer;Francis;N Engl J Med,2018

4. Adjuvant ovarian suppression in premenopausal breast cancer;Francis;N Engl J Med,2015

5. Endocrine therapy plus zoledronic acid in premenopausal breast cancer;Gnant;N Engl J Med,2009

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adjuvant endocrine therapy choices in premenopausal patients with hormone receptor-positive early breast cancer: Insights from the prospective GIM23-POSTER study;The Breast;2024-10

2. Revisiting ovarian function suppression with GnRH agonists for premenopausal women with breast cancer: Who should use and the impact on survival outcomes;Cancer Treatment Reviews;2024-09

3. Bone-active drugs in premenopausal women with breast cancer under hormone-deprivation therapies;European Journal of Endocrinology;2024-07-26

4. MASCC/ISOO Clinical Practice Statement: Adjuvant bone-modifying agents in primary breast cancer patients - prevention of medication-related osteonecrosis of the jaw;Supportive Care in Cancer;2024-07-25

5. Bone-modifying agents for reducing bone loss in women with early and locally advanced breast cancer: a network meta-analysis;Cochrane Database of Systematic Reviews;2024-07-09